Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study

MicroAbstract In POSITION, patients with unresectable non-small cell lung cancer who may face challenges receiving consolidation durvalumab due to incomplete concurrent chemoradiotherapy (cCRT) or disease progression were characterised. Higher comorbidity burden, race (Black vs White), disease stage (IIIB/C vs IIIA), cerebrovascular, and renal disease were associated with ineligibility. Outcomes for these patients need to be optimised. Introduction Many patients with unresectable stage III non-small-lung cancer (NSCLC) may face challenges in receiving consolidation durvalumab following concurrent chemoradiotherapy (cCRT) due to incomplete cCRT or disease progression. The retrospective POSITION study characterized this population. Methods Adults with unresectable stage III NSCLC diagnosed between 2010–2021 who received cCRT were identified from TEMPUS Oncology (database). Among these patients, we estimated proportions with incomplete cCRT or progression during/within 42 days of cCRT and assessed overall survival (OS). Factors associated with incomplete cCRT or progression during/within 42 days of cCRT were identified via multivariable logistic regression. Results Of 2,076 eligible patients, 23.0% had incomplete cCRT (Group A), 12.7% experienced progression during/within 42 days of cCRT (Group B), and 64.3% completed cCRT without progression (Group C). Median OS (95% CI) was 21.6 (17.2–28.0), 10.1 (7.2–12.5), and 32.4 (29.8–34.6) months for Groups A, B, and C, respectively. Landmark 60-month OS rates were 26.3%, 11.6% and 33.2% for Groups A, B and C, respectively. Higher comorbidity burden (Charlson Comorbidity Index) and Black (vs White) race were associated with higher likelihood of incomplete cCRT. Stage IIIB/C (vs IIIA), cerebrovascular, and renal disease were associated with higher likelihood of progression during/within 42 days of cCRT. Conclusion In POSITION, 35.7% of patients had incomplete cCRT or progressed during/within 42 days of cCRT and may have faced challenges receiving consolidation durvalumab; race, disease stage, and comorbidities were associated with incomplete cCRT or progression.